Stonebridge Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Stonebridge Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,190	Closed	-$201K	–	115
2019 Q3	$201K	Sell	1,190 -390	-25%	-$69K	0.09%	111
2019 Q2	$290K	Sell	1,580 -925	-37%	-$162K	0.11%	96
2019 Q1	$461K	Hold	2,505	–	–	0.17%	89
2018 Q4	$415K	Sell	2,505 -57	-2%	-$9.88K	0.17%	88
2018 Q3	$494K	Sell	2,562 -1,160	-31%	-$207K	0.17%	83
2018 Q2	$630K	Hold	3,722	–	–	0.23%	72
2018 Q1	$601K	Hold	3,722	–	–	0.22%	74
2017 Q4	$588K	Sell	3,722 -225	-6%	-$33.3K	0.21%	77
2017 Q3	$600K	Sell	3,947 -25	-0.6%	-$3.76K	0.23%	74
2017 Q2	$512K	Sell	3,972 -1,809	-31%	-$218K	0.2%	79
2017 Q1	$633K	Sell	5,781 -1,100	-16%	-$96.8K	0.26%	68
2016 Q4	$507K	Buy	+6,881	New	+$560K	0.21%	74

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Stonebridge Capital Management's VRTX Position: Q4 2019 in Review

Stonebridge Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 1,190 shares — an estimated $201K sold.

Stonebridge Capital Management first reported a position in VRTX in Q4 2016 and held it in 12 quarters. The position peaked at $633K in Q1 2017. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

Stonebridge Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Stonebridge Capital Management sold 1,190 Vertex Pharmaceuticals shares in Q4 2019, an estimated $201K.
Stonebridge Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 12 quarters.
Stonebridge Capital Management's Vertex Pharmaceuticals position peaked at $633K in Q1 2017.
814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Stonebridge Capital Management's 13F filing for Q4 2019, filed 2 Jan 2020.